Monte Rosa will remain responsible for completion of the ongoing Phase 1 clinical study of MRT-6160 and is also eligible to ...
Wells Fargo analyst Derek Archila downgraded Monte Rosa Therapeutics (GLUE) to Equal Weight from Overweight with a price arget of $11, down from $14. The firm thinks the stock’s upside is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback